Ezetimibe, an inhibitor of Niemann-Pick C1-like 1 protein, decreases cholesteryl ester transfer protein in type 2 diabetes mellitus

Endocrine Journal

Shun Ishibashi¹  Hiroaki Yagyu¹  Michiaki Miyamoto¹  Shuichi Nagashima¹  Manabu Takahashi¹  Jun-ichi Osuga¹  Kenta Okada¹ 

[1] Division of Endocrinology and Metabolism, Jichi Medical University, Shimotsuke 329-0498, Japan

关键词: Ezetimibe;    Type 2 diabetes;    High-density lipoproteins;    Lecithin-cholesterol acyltransferase;    Cholesteryl ester transfer protein;   

DOI  :  10.1507/endocrj.EJ12-0132

学科分类：内分泌与代谢学

来源: Japan Endocrine Society

【 摘 要 】

References(28)To address the effects of ezetimibe on high-density lipoprotein (HDL) metabolism, the HDL subclasses, cholesteryl ester transfer protein (CETP), and lecithin-cholesterol acyltransferase (LCAT) were measured in patients with type 2 diabetes mellitus (T2DM).Twenty-three hypercholesterolemic patients with T2DM were treated with 10 mg of ezetimibe daily for 12 weeks.Plasma total cholesterol (TC), low-density lipoprotein (LDL)-cholesterol (C), HDL-C, HDL2-C, HDL3-C, CETP mass, and LCAT activity were measured.HDL-C and HDL2-C increased by 5% (pppp2-C and CETP mass, whereas a significant inverse relationship was observed between HDL3-C and CETP mass.Furthermore, the change in HDL-C was positively correlated with the change in LCAT activity.In conclusion, ezetimibe may affect HDL metabolism and reverse cholesterol transport, especially CETP, in T2DM.These observations may provide some insights into how ezetimibe prevents atherosclerosis.

【 授权许可】

Unknown